Suprachoroidal Triamcinolone Acetonide for Noninfectious Uveitis: Real-World Impact on Clinical Outcomes

To evaluate clinically relevant outcomes following suprachoroidal triamcinolone acetonide (TA) injection in eyes with noninfectious uveitis.

Retrospective interventional case series.

Sixty-one eyes (51 patients) who underwent suprachoroidal TA injection between January 1, 2022 and July 1, 2024 were included from a single institution. Main outcome measures included change in central subfield thickness (CST) and best-corrected visual acuity (BCVA) at 6, 12, and 24 weeks in eyes with macular edema and improvement in fluorescein angiography (FA) score at 6 weeks in eyes who underwent FA.

Fifty-two eyes underwent suprachoroidal TA injection for uveitic macular edema. Mean CST improved from 437.61 microns at time of injection to 348.17 microns 6 weeks after (mean difference 89.44 microns, p < 0.0001, n = 47). Additional treatment for macular edema was required for 17% (8/48 eyes), 48% (14/29 eyes), and 41% (9/22 eyes) of eyes that returned for follow-up at 6, 12, and 24 weeks, respectively. Of the 17 eyes that returned for follow-up at all visits (6, 12, and 24 weeks), 41.2% (7/17 eyes) did not require any additional treatment during the 24-week follow-up period. Ten eyes underwent FA at time of injection and 6 weeks later. The mean FA score improved from 11.74 to 9.14 (mean difference 2.60, p = 0.047). No serious adverse events occurred.

Suprachoroidal TA resulted in significant improvement in outcome measures, including central subfield thickness in eyes with macular edema, and leakage on fluorescein angiography, with a favorable side effect profile in real-world clinical practice.